ArticleBMC ophthalmology2026
Effects of coenzyme Q10 on retinal inflammation in streptozotocin-induced diabetic rats.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundInflammation, oxidative stress, and apoptosis play important roles in diabetes-induced retinal injury. Coenzyme Q10 (CoQ10) is an endogenous antioxidant involved in mitochondrial energy metabolism and cellular protection. This study aimed to investigate the effects of CoQ10 on diabetes-induced retinal injury in a streptozotocin-induced diabetic rat model.
methodsDiabetes was induced in rats using streptozotocin. The animals were divided into 1- and 2-month experimental groups, each consisting of control, diabetic, CoQ10-treated, and diabetic + CoQ10 groups. CoQ10 was administered via oral gavage at a dose of approximately 30 mg/kg/day. Blood samples were collected for biochemical analysis, and retinal tissues were evaluated using immunohistochemical staining for tumor necrosis factor-alpha (TNF-α), nuclear factor kappa-B (NFκB), Bcl-2-associated X protein (Bax), vascular endothelial growth factor (VEGF), and VEGF receptor (VEGFR).
resultsIn the 2-month experimental group, SOD, GSH, and CAT levels were significantly higher in diabetic rats compared with the diabetic + CoQ10 group. Immunohistochemical analysis showed decreased staining intensities of VEGF, VEGFR, NFκB, and Bax in the diabetic + CoQ10 group compared with the diabetic group at the first month. In the second month, TNF-α, NFκB, and CD45 staining intensities were significantly reduced in the diabetic + CoQ10 group compared with the diabetic group.
conclusionThese findings suggest that CoQ10 may modulate inflammatory, apoptotic, and oxidative stress pathways in diabetes-induced retinal injury. However, the protective effects appear to vary depending on the duration of diabetes. Further studies are required to clarify the potential role of CoQ10 in diabetic retinal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.